TL Genomics is a developer of a prenatal diagnosis technology created to isolate fetal nucleated red blood cells in maternal blood.
TL Genomics's investors include Shizuoka FundSupport, SMBC Venture Capital, Nissay Capital, NEDO, DBJ Capital.
TL Genomics is headquartered in Koganei, Japan.
TL Genomics is a developer of a prenatal diagnosis technology created to isolate fetal nucleated red blood cells in maternal blood.
TL Genomics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TL Genomics — Funding & Investors." VCBacked, March 17, 2026, https://www.vcbacked.co/company/tl-genomics. Accessed July 20, 2026.
VCBacked. (2026). TL Genomics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/tl-genomics
{{cite web |title=TL Genomics — Funding & Investors |url=https://www.vcbacked.co/company/tl-genomics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated